Dexela Ltd is pleased to announce that it has signed a new strategically important contract with XCounter AB (publ) (AIM: XCT), the innovation and development house in 3D technologies for leading X-ray companies.
Dexela and XCounter have successfully cooperated during 2006 and have now signed a new and larger cooperation contract. Dexela will develop software for three dimensional (3D) image reconstruction for XCounter's 3D mammography product platform, XC Mammo -3T. The reconstruction software will have full DICOM compatibility. The software development will be conducted in accordance with the FDA regulations for software in medical devices.
"I am delighted that Dexela will be deepening its collaboration with XCounter. Dexela's advanced image reconstruction software will help to realise the enormous clinical potential of XCounterLs unique 3D technologies," says Edward Bullard, CEO of Dexela.
Dexela is a leading developer of 3D reconstruction and diagnostic review software and has executed advanced development projects for several well known X-ray manufacturers.
"I am very pleased to expand our cooperation with Dexela. The advanced image reconstruction software of Dexela combined with the unique image quality of XC Mammo -3T will result in better 3D images for breast cancer diagnosis. We look forward to a long and fruitful partnership with Dexela," says Tom Francke, CEO of XCounter.
For further information, please contact:
Dexela Limited
Edward Bullard, Chief Executive Officer
Tel: +44 845 229 7750
XCounter AB (publ)
Dr Tom Francke, Chief Executive Officer
Tel: +46 8 622 23 00
Buchanan Communications
Diane Stewart/ Mark Court/Rebecca Skye Dietrich Tel: +44 (0) 20 7466 5000
Notes to Editors
About Dexela
Dexela is developing accurate and sensitive 3D breast imaging technology for the early detection of breast cancer, known as Tomosynthesis. Conventional mammography has a significant rate of both false negatives and false positives, particularly in younger women.
Dexela is developing innovative technology for 3D breast imaging, which promises to significantly reduce both false negatives and false positives, allowing the earlier detection of cancer while reducing the occurrence of call-backs. Dexela has developed powerful techniques to acquire, process and visualize data from 3D X-ray breast imaging. Dexela is playing a central role in this field through relationships with medical device manufacturers.
About XCounter
XCounter is an innovation and development house for the leading X-ray companies.
XCounter offers ready-to-market imaging systems based on unique 3D technologies. The company was founded in 1997 by researchers with NASA and CERN experience in space research. It is listed on the London Stock Exchange's AIM market. XCounter is based in Stockholm, Sweden.
XCounter's unique and proprietary technology, XCT -3T, has a number of major advantages over competing technologies. XCT -3T enables production of 3D images at low levels of radiation dose. This means that it is safer for patients when compared to existing imaging techniques.
XCounter currently has four product platforms in development based on XCT -3T, XCounter's unique technology for 3-dimensional X-ray imaging. These are the XC Mammo -3T for breast cancer screening, the XC MP -3T for general body imaging and the two platforms for preventive cardiac imaging, XC Cardio -3T for functional imaging of the heart and XC Cardio -4T for 3D imaging of the beating heart.
These products target the major part of the US$7 billion digital X-ray system market, and have the potential to expand the market through the introduction of novel low-dose screening applications.
The images are of superior image quality than current 3D techniques. Consequently XCT - 3T should enable better and earlier diagnosis of diseases by radiologists, and save money and reduce anxiousness among patients by reducing the number of false recalls.
More information and our press releases can be accessed at
www.XCounter.se